ImmunoGen, Inc. IMGN
Day range unavailable
52-week range unavailable
- Market cap
- 8.72B
- Revenue (ttm)
- 287.61M
- Profit margin
- -25.56%
- Shares out
- 279.35M
- Forward P/E
- 86.75
- Beta
- 1.17
- Analysts
- Buy
- Price target
- 25.50 (-18.4%)
- Earnings date
- Mar 6, 2024
2Y +25.69 (+463.72%)
Key statistics
- Enterprise value
- 7.79B
- PEG ratio
- 0.00
- Price / sales
- 30.33
- Price / book
- 15.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 637.70%
- Free cash flow
- -133.20M
- Total cash
- 605.53M
- Total debt
- 84.33M
- Return on equity
- -19.88%
- Short % of float
- 7.40%
- 50-day average
- 29.71
- 200-day average
- 19.72
Analyst view
Consensus: buy
- Target (low)
- 16.00
- Target (mean)
- 25.50
- Target (high)
- 31.00
- Strong buy4
- Buy1
- Hold3
- Sell1
- Strong sell0
Next earnings
Mar 6, 2024
Expected Mar 6, 2024. Consensus EPS estimate 0.13.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 6, 2024 | Dec 1, 2023 | 0.13 | — | — | — |
| Nov 2, 2023 | Sep 1, 2023 | 0.02 | — | — | — |
| Jul 31, 2023 | Jun 1, 2023 | -0.16 | — | — | — |
| Apr 28, 2023 | Mar 1, 2023 | -0.25 | — | — | — |
| Mar 1, 2023 | Dec 1, 2022 | -0.29 | — | — | — |
| Nov 4, 2022 | Sep 1, 2022 | -0.26 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2023 | Oppenheimer | init | — | Perform |
| Sep 12, 2023 | JP Morgan | up | Neutral | Overweight |
| Aug 28, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 1, 2023 | Barclays | main | Overweight | Overweight |
| Jul 31, 2023 | Canaccord Genuity | main | Buy | Buy |
| Jul 31, 2023 | BMO Capital | main | Outperform | Outperform |
About ImmunoGen, Inc.
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immunogen.com
News
Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
Earnings Scheduled For November 2, 2023 
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023 
Earnings Scheduled For July 31, 2023 
Why First Republic Bank Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Earnings Scheduled For March 1, 2023
- HUYA, Tencent Music Entertainment, Taiwan Semiconductor Manufacturing, And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Earnings Scheduled For November 4, 2022 - Earnings Scheduled For July 29, 2022
- Stocks That Hit 52-Week Lows On Tuesday
Your note
Sign in to keep a note on IMGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARBUCKLE STUART A | Director | Stock Award(Grant) | Dec 28, 2023 | 5,381 |
| COEN STACY ANN | Officer | Sale | Feb 4, 2024 | 73,274 |
| ENYEDY MARK J | Chief Executive Officer | Sale | Feb 4, 2024 | 584,397 |
| GOLDBERG MARK ALAN | Director | Stock Award(Grant) | Dec 28, 2023 | 60,720 |
| LENTINI RENEE | Officer | Sale | Feb 4, 2024 | 14,723 |
| PETERSON KRISTINE | Director | Sale | Nov 29, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.40% | 20,904,986 | 394.48M | Jun 29, 2023 |
| Vanguard Group Inc | 8.40% | 20,899,026 | 394.36M | Jun 29, 2023 |
| Redmile Group, LLC | 7.12% | 17,730,417 | 334.57M | Jun 29, 2023 |
| Janus Henderson Group PLC | 6.23% | 15,499,788 | 292.48M | Jun 29, 2023 |
| Wellington Management Group, LLP | 3.92% | 9,752,899 | 184.04M | Jun 29, 2023 |
| Point72 Asset Management, L.P. | 3.50% | 8,712,142 | 164.40M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.25% | 8,078,738 | 152.45M | Jun 29, 2023 |
| iShares Russell 2000 ETF | 2.22% | 5,530,172 | 87.60M | Aug 30, 2023 |
| Janus Henderson Global Life Sciences Fund | 1.49% | 3,718,755 | 70.17M | Jun 29, 2023 |
| Vanguard Small-Cap Index Fund | 1.33% | 3,301,242 | 62.29M | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 1.30% | 3,232,709 | 61.00M | Jun 29, 2023 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.14% | 2,841,588 | 45.01M | Aug 30, 2023 |